Li Ki Fung Cliff, Ho Hee Hwa, Jafary Fahim H, Ong Paul Jau Lueng
Department of Cardiology, Tan Tock Seng Hospital, Singapore 308444.
Acta Cardiol Sin. 2020 Nov;36(6):675-680. doi: 10.6515/ACS.202011_36(6).20200810A.
High-risk "protected" percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) devices, particularly the Impella axial pump, has emerged as a viable treatment option for high-risk patients with satisfactory clinical outcomes. High-risk and complex interventions have mostly remained within the domain of surgical centers. We report on an early "protected" PCI experience using MCS with the Impella flow pump at a high-volume PCI hospital without on-site surgery. A total of 5 patients underwent elective "protected" PCI utilizing MCS with Impella at our institution. The mean left ventricular ejection fraction was 28 ± 10% and all patients had triple vessel coronary artery disease with the majority having a high SYNTAX score. Device implantation and procedural success were achieved in all cases with no intraprocedural or access site complications. All patients were alive at 30 days and clinically well. The Impella unloads the ventricle, improves forward cardiac output and lowers myocardial oxygen demand, thereby improving mean arterial pressure and coronary perfusion. Device insertion is relatively quick and the "learning curve" is short, centering mainly around managing large bore access. Our limited experience suggests that not only is high-risk PCI with Impella support feasible in a non-surgical center, but that it may be crucial to enable success.
使用机械循环支持(MCS)设备,特别是Impella轴流泵进行的高风险“保护性”经皮冠状动脉介入治疗(PCI),已成为高危患者可行的治疗选择,临床结果令人满意。高风险和复杂的介入治疗大多仍局限于外科中心。我们报告了在一家没有现场手术的高容量PCI医院使用Impella流量泵进行MCS的早期“保护性”PCI经验。共有5例患者在我们机构接受了使用Impella进行MCS的择期“保护性”PCI。平均左心室射血分数为28±10%,所有患者均患有三支冠状动脉疾病,大多数患者SYNTAX评分较高。所有病例均成功植入设备并完成手术,无术中或穿刺部位并发症。所有患者在30天时均存活且临床状况良好。Impella可减轻心室负荷,改善心脏前向输出并降低心肌氧需求,从而提高平均动脉压和冠状动脉灌注。设备插入相对较快,“学习曲线”较短,主要围绕大口径穿刺管理。我们有限的经验表明,不仅在非手术中心使用Impella支持进行高风险PCI是可行的,而且这可能是取得成功的关键。